| Authors: |
Luff DH; Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, United Kingdom., Wojdyla K; Mass Spectrometry Facility, The Babraham Institute, Cambridge, United Kingdom.; Signalling Programme, The Babraham Institute, Cambridge, United Kingdom., Oxley D; Mass Spectrometry Facility, The Babraham Institute, Cambridge, United Kingdom., Chessa T; Signalling Programme, The Babraham Institute, Cambridge, United Kingdom., Hudson K; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hawkins PT; Signalling Programme, The Babraham Institute, Cambridge, United Kingdom., Stephens LR; Signalling Programme, The Babraham Institute, Cambridge, United Kingdom., Barry ST; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Okkenhaug K; Department of Pathology, University of Cambridge, Cambridge, United Kingdom. |